NCT07916480Phase 3Recruiting

Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis

Study sponsor: Arcutis Biotherapeutics, Inc. · ARQT

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-04-27Estimated
Enrollment · participants415Estimated
Source updated2026-11-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Not yet recruiting. After: Recruiting.

Check registry source